Cargando…

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects

Activation of the brain dopamine D1 receptor has attracted attention because of its promising role in neuropsychiatric diseases. Although efforts to develop D1 agonists have been challenging, a positive allosteric modulator (PAM), represents an attractive approach with potential better drug‐like pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilbraham, Darren, Biglan, Kevin M., Svensson, Kjell A., Tsai, Max, Kielbasa, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048550/ https://www.ncbi.nlm.nih.gov/pubmed/33029934 http://dx.doi.org/10.1002/cpdd.874

Ejemplares similares

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease
por: Wilbraham, Darren, et al.
Publicado: (2021)

Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo‐Controlled Trial
por: Biglan, Kevin, et al.
Publicado: (2021)

Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor
por: Zhuang, Youwen, et al.
Publicado: (2021)

The Molecular Mechanism of Positive Allosteric Modulation at the Dopamine D1 Receptor
por: Goldberg, Alexander, et al.
Publicado: (2023)

The molecular mechanism of positive allosteric modulation at the dopamine D1 receptor
por: Goldberg, Alexander, et al.
Publicado: (2023)

An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis
por: Svensson, Kjell A., et al.
Publicado: (2017)

Effects of DPTQ, a novel positive allosteric modulator of the dopamine D1 receptor, on spontaneous eye blink rate and spatial working memory in the nonhuman primate
por: Castner, Stacy A., et al.
Publicado: (2023)

Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor
por: Fyfe, Tim J., et al.
Publicado: (2021)

Evidence for the existence of dopamine D2R and Sigma 1 allosteric receptor-receptor interaction in the rat brain: role in brain plasticity and cocaine action
por: Pinton, Luca, et al.
Publicado: (2015)

The Role of Lipids in Allosteric Modulation of Dopamine D(2) Receptor—In Silico Study
por: Żuk, Justyna, et al.
Publicado: (2022)

Discovery of “Molecular Switches” within a Series of mGlu(5) Allosteric Ligands Driven by a “Magic Methyl” Effect Affording Both PAMs and NAMs with In Vivo Activity, Derived from an M(1) PAM Chemotype
por: Barbaro, Lisa, et al.
Publicado: (2021)

Differential allosteric modulation within dopamine D(2)R - neurotensin NTS1R and D(2)R - serotonin 5-HT(2A)R receptor complexes gives bias to intracellular calcium signalling
por: Plach, Michael, et al.
Publicado: (2019)

Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome
por: Luo, Linlin, et al.
Publicado: (2016)

Mechanism of Allosteric Activation of SAMHD1 by dGTP
por: Ji, Xiaoyun, et al.
Publicado: (2013)

Activating Ly-49d and Inhibitory Ly-49a Natural Killer Cell Receptors Demonstrate Distinct Requirements for Interaction with H2-D(d)
por: Nakamura, Mary C., et al.
Publicado: (2000)

The action of a negative allosteric modulator at the dopamine D(2) receptor is dependent upon sodium ions
por: Draper-Joyce, Christopher J., et al.
Publicado: (2018)

Dopamine D1 Receptor in Cancer
por: Sobczuk, Paweł, et al.
Publicado: (2020)

Effects of the Dopamine D2 Allosteric Modulator, PAOPA, on the Expression of GRK2, Arrestin-3, ERK1/2, and on Receptor Internalization
por: Basu, Dipannita, et al.
Publicado: (2013)

Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P(1) Receptor Modulator in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2017)

RAG-1 and Ly6D Independently Reflect Progression in the B Lymphoid Lineage
por: Zhang, Qingzhao, et al.
Publicado: (2013)

Pharmacokinetics of the Long‐Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function
por: Linnebjerg, Helle, et al.
Publicado: (2016)

2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D(1) Receptor for Parkinson’s Disease
por: García-Cárceles, Javier, et al.
Publicado: (2022)

Developmental and communicative interrelations of Ly123 and Ly1 cell sets
Publicado: (1980)

Voltage-Dependent Dopamine Potency at D(1)-Like Dopamine Receptors
por: Ågren, Richard, et al.
Publicado: (2020)

Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D(1) receptor positive allosteric modulator in patients with schizophrenia
por: Desai, Amit, et al.
Publicado: (2020)

Development of peptidomimetic ligands of Pro-Leu-Gly-NH(2) as allosteric modulators of the dopamine D(2) receptor
por: Bhagwanth, Swapna, et al.
Publicado: (2013)

Evidence for Two Modes of Binding of the Negative Allosteric Modulator SB269,652 to the Dopamine D(2) Receptor
por: Ågren, Richard, et al.
Publicado: (2021)

Ly6D(+)Siglec-H(+) precursors contribute to conventional dendritic cells via a Zbtb46(+)Ly6D(+) intermediary stage
por: Lutz, Konstantin, et al.
Publicado: (2022)

Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol
por: Tsai, Max, et al.
Publicado: (2020)

Isolation and Characterization of [D-Leu(1)]microcystin-LY from Microcystis aeruginosa CPCC-464
por: LeBlanc, Patricia, et al.
Publicado: (2020)

The Signaling and Pharmacology of the Dopamine D1 Receptor
por: Jones-Tabah, Jace, et al.
Publicado: (2022)

Evidence against dopamine D1/D2 receptor heteromers
por: Frederick, Aliya L., et al.
Publicado: (2015)

A Novel Dopamine Receptor Signaling Unit in Brain: Heterooligomers of D1 And D2 Dopamine Receptors
por: George, Susan R., et al.
Publicado: (2007)

The Appetite Suppressant D-norpseudoephedrine (Cathine) Acts via D1/D2-Like Dopamine Receptors in the Nucleus Accumbens Shell
por: Kalyanasundar, B., et al.
Publicado: (2020)

Expression of Ly 1, Ly 2, Thy 1, and TL differentiation antigens on mouse T-cell tumors
Publicado: (1978)

Mouse Ly-49D Recognizes H-2D(d) and Activates Natural Killer Cell Cytotoxicity
por: Nakamura, Mary C., et al.
Publicado: (1999)

Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer
por: Bihorel, S, et al.
Publicado: (2017)

Human Secreted Ly-6/uPAR Related Protein-1 (SLURP-1) Is a Selective Allosteric Antagonist of α7 Nicotinic Acetylcholine Receptor
por: Lyukmanova, Ekaterina N., et al.
Publicado: (2016)

Ligand-dependent Inhibition of CD1d-restricted NKT Cell Development in Mice Transgenic for the Activating Receptor Ly49D
por: Voyle, Roger B., et al.
Publicado: (2003)

The Ly-49D Receptor Activates Murine Natural Killer Cells
por: Mason, L.H., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_kuueo64pcc3gtv6aj0bfjgsbuh